NEW YORK, June 16, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Napco Security Technologies, Inc. (NASDAQ: NSSC).Shareholders who purchased shares of NSSC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/napco-security-technologies-inc-loss-submission-form/?id=152939&from=4C ...

NEW YORK, June 16, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of West Pharmaceutical Services, Inc. (NYSE: WST).Shareholders who purchased shares of WST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/west-pharmaceutical-services-inc-loss-submission-form/?id=152943&from=4CLA ...

NEW YORK, June 16, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of DoubleVerify Holdings, Inc. (NYSE: DV).Shareholders who purchased shares of DV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/doubleverify-holdings-inc-loss-submission-form-2/?id=152951&from=4CLASS PERIOD: Nov ...

NEW YORK, June 16, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO).Shareholders who purchased shares of ZBIO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/zenas-biopharma-inc-loss-submission-form/?id=152937&from=4CLASS PERIOD: This lawsui ...

Core Insights - The launch of Nintendo Switch 2 is generating excitement among gamers and retailers, with Best Buy expected to benefit from increased demand, although broader financial and macroeconomic challenges persist [2][3] Financial Performance - Best Buy's stock has declined 13% year-to-date, underperforming the S&P 500 [3] - In Q1 FY 2026, Best Buy reported a 2% decrease in net sales and a 5% decline in diluted EPS, with net income falling 18% to $202 million [3][6] - Revenue for Q1 FY 2026 was $8.77 billion, with comparable sales down 0.7% year-over-year [6] Economic Challenges - Best Buy faces significant cost pressures due to tariffs, with 30-35% of goods sourced from China facing tariffs up to 30% and 40% from other countries facing a 10% tariff [7] - The company has raised prices and is urging vendors to diversify sourcing to mitigate costs [7] Future Outlook - For FY 2026, Best Buy revised its revenue expectations to a range of $41.1 billion to $41.9 billion, down from previous estimates [8] - Adjusted earnings per share are expected to be between $6.15 and $6.30, indicating a cautious outlook due to ongoing inflation and consumer spending behavior [8] Valuation Metrics - Best Buy is currently trading at 18 times trailing earnings, higher than its four-year average P/E ratio of 12 times, but the forward P/E ratio is about 11x, suggesting a more moderate valuation [9][10] - Analysts' price targets indicate an upside of only 4% from current prices, reflecting limited optimism amid weak fundamentals [10] Historical Performance - Best Buy has a history of significant stock declines during economic downturns, with drops of nearly 55% during the 2022 inflation surge and 67% during the 2008 financial crisis [4][5]

Group 1 - The stock market is currently influenced by macroeconomic fears, particularly regarding the impact of tariffs on the U.S. economy and the effects of rising geopolitical tensions on global growth [1] - Gary Alexander has extensive experience in covering technology companies and has been involved with seed-round startups, providing insights into current industry themes [1] Group 2 - Alexander has been a contributor to Seeking Alpha since 2017 and has been quoted in various web publications, indicating his influence and reach within the investment community [1]

Core Insights - AbbVie is experiencing stability in price action and offers attractive dividend yields, but there are underlying issues in the investment thesis beyond the aging Humira patent cliff [1] Group 1: Company Analysis - AbbVie is facing challenges related to the expiration of the Humira patent, which is a significant concern for its future revenue streams [1] - The company has a strong focus on equity valuation, market trends, and portfolio optimization to identify high-growth investment opportunities [1] Group 2: Analyst Background - The analysis is conducted by a seasoned analyst with over 20 years of experience in quantitative research, financial modeling, and risk management, emphasizing a long-term perspective on value creation [1] - The analyst has previously held a Vice President position at Barclays, leading teams in model validation and stress testing, showcasing a deep expertise in both fundamental and technical analysis [1]

Core Insights - Insmed Inc experienced a significant stock surge of 45% in the last month, driven by successful Phase IIb trial results for its inhalation therapy TPIP in pulmonary arterial hypertension (PAH) [2] - The company is currently trading at a high valuation of 35 times sales, which translates to a low sales yield of 2.8%, raising concerns about its sustainability [3] - Insmed's stock premium is primarily attributed to the positive trial results and a $750 million capital raise aimed at pipeline expansion, leading to investor optimism [4][5] Financial Performance - Insmed projects global revenues for its product ARIKAYCE to be between $405 million and $425 million in 2025, indicating an 11-17% growth compared to 2024 [6] - The company is expected to remain unprofitable into 2026 due to ongoing investments in research and development for pipeline products [6] Future Outlook - The FDA's decision on brensocatib in August and the initiation of Phase 3 trials for TPIP are critical upcoming milestones that could significantly impact Insmed's stock performance [7] - Successful execution of Phase 3 trials and commercial launches of both brensocatib and TPIP will be essential for maintaining the current premium valuation [7][8]

Group 1 - Greystone Housing Impact Investors LP (GHI) has seen a 10.1% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days and offers a dividend yield of 12.4%, significantly higher than the industry average of 0.0% [1] - Virtu Financial, Inc. (VIRT) has experienced an 8.5% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days, with a dividend yield of 2.3%, also above the industry average of 0.0% [2] - Flexsteel Industries, Inc. (FLXS) has had a 7.4% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2]

Vancouver, Canada, June 16, 2025 (GLOBE NEWSWIRE) -- Spirit Blockchain Capital Inc. (CSE: SPIR) (“Spirit” or the “Company”) is pleased to announce that on January 30, 2025 it engaged 2686363 Ontario Corporation dba CanaCom Group (the “Service Provider”) firms to design, develop and execute a company awareness program through TheDeepDive.ca blog that will help engage the online investor community into understanding Spirit. The term of the engagement is for a period of 12 months from February 3, 2025 (being t ...